Fluorimetric Determination of Rivastigmine in Rat Plasma by a Reverse Phase — High Performance Liquid Chromatographic Method

Abstract

A sensitive and selective high performance liquid chromatographic (HPLC) method was developed and validated for the rapid quantification of rivastigmine (CAS 123441-03-2) in micro quantity in rat plasma samples. The chromatographic separation was achieved with a reverse phase monomeric column C₁₈ (4.6 × 250 mm, 5 µm) and the mobile phase consisted of acetonitrile and 20 mmol/L phosphate buffer pH 3.0 (25:75) with a flow rate of 1 mL/min. The effluents were measured by fluorimetric detection with excitation and emission wavelengths at 220 nm and 293 nm, respectively. The calibration curve was linear (r² >0.99) ranging from 25–3000 ng/mL and the lower limit of quantification was 25 ng/mL. The method was validated with excellent sensitivity, selectivity, accuracy, precision, recovery and stability. The method has been successfully applied in a pharmacokinetic study of rivastigmine in rats.

Key words

Acetylcholine esterase inhibitors - CAS 123441-03-2 - Rivastigmine, bioanalytical method, fluorimetric detection, HPLC, rat plasma, validation

• References

• 1 Cummings JL, Cole G. Alzheimer disease. JAMA. 2002; 287: 2335-2338
• 2 Shukla VK, Nicolass O, Doug C. Pathology of Alzheimer disease. Tech Rep. 2000; 11: 1-64
• 3 Ronald JP. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther. 1998; 20 (4) 634-637
• 4 Bowen DM, Francis PT, Chessel IP, MT Webster. Alzheimer’s Disease Clinical and Treatment Perspectives. Chichester. (England): John Wiley & Sons; 1995
• 5 Srinivasu MK, Mallikarjuna Rao B, Shyam Sundar Reddy B, Rajeneder Kumar P, Chandrasekhar KB, Pradeep K et al. A validated chiral liquid chromatographic method for the enantiomeric separation of rivastigmine hydrogen tartarate, a Cholinesterase inhibitor. J Pharm Biomed Anal. 2005; 38: 320-325
• 6 Pommier F, Frigola R. Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B. 2003; 784: 301-313
• 7 Enz A, Chappuis A, Dattier A. A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry. Biomed Chromatogr. 2004; 18 (3) 160-166
• 8 Frankfort SV, Ouwehand M, van Maanen MJ, Rosing H, Tulner LR, Beijnen JH. A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006; 20 (22) 3330-3336
• 9 Bhatt J, Subbaiah G, Kampli S, Shah B, Nigam S, Patel M et al. A rapid and sensitive liquid chromatography – tandem mass spectrometry (LC - MS/MS) method for the estimation of rivastigmine in human plasma. J Chromatogr B. 2007; 852: 115-121
• 10 Yunfei S, Chunhui D, Zhen L, Taomin H, Bei Y, Gengli D. Headspace solid-phase microextraction and capillary gas chromatographic-mass spectrometric determination of rivastigmine in canine plasma samples. J Chromatogr B. 2004; 806: 271-276
• 11 Mallikarjuna Rao B, Srinivasu MK, Neelu B, Ravi R, Pradeep M, Om Reddy G et al. A stability indicating LC method for rivastigmine hydrogen tartrate. J Pharm Biomed Anal. 2005; 37: 57-63
• 12 Kavalirova A, Pospisilova M, Karlicek R. Enantiomeric analysis of rivastigmine in pharmaceuticals by cyclodextrin-modifled capillary zone electrophoresis. Anal Chim Acta. 2004; 525: 43-51
• 13 Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry, Bioanalytical Method Validation, May 2001. Available at. http://www.fda.gov/cder/guidance/4252fnl.pdf